Rheumatology Network Newsletter

To view this email as a web page, click here.

New Treatment Option for Systemic Sclerosis-Associated Interstitial Lung Disease

The U.S. Food and Drug Administration has approved nintedanib (Ofev, Boehringer Ingelheim Pharmaceuticals) capsules to slow the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD), which is a progressive lung disease that can be debilitating and life-threatening.

Osteoarthritis News Roundup: Opioids, NSAIDs and More

In today's news roundup, we focus on recent advances made in osteoarthritis that touch on cardiovascular issues, bone spurs and treatment modalities.

Knee Osteoarthritis Pain Intensity is Gender-Related

Levels of the biomarker urine C-telopeptide of cross-linked collagen type II (uCTX-II) are independently associated with radiographic severity and pain intensity in knee osteoarthritis, say researchers writing in Arthritis Research & Therapy this month.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.